10-Q: Oramed Pharmaceuticals Reports Q1 2025 Results, Revenue Boosted by HTIT Agreement

Oramed Pharmaceuticals reports a net loss for Q1 2025, but sees revenue increase due to the HTIT License Agreement and progresses with strategic real estate investments.

Summary

• Oramed Pharmaceuticals Inc. reported its financial results for the quarter ended March 31, 2025.
• The company experienced a net loss of $7.642 million, or $0.19 per share, compared to a net income of $1.534 million, or $0.04 per share, for the same period in 2024.
• Revenues increased to $2.0 million due to the recognition of revenue related to the HTIT License Agreement.
• Research and development expenses increased by 87% to $2.206 million, driven by preparations for a new Phase 3 clinical trial.
• General and administrative expenses increased by 29% to $2.307 million, mainly due to higher stock-based compensation expenses.
• The company's cash and cash equivalents increased to $74.516 million as of March 31, 2025.
• Oramed is progressing with its joint venture agreement with Hefei Tianhui Biotech Co., Ltd. (HTIT), although the closing is currently on hold due to ongoing U.S.-China trade tensions.
• The company is also pursuing strategic real estate investments, with board approval for investments of up to $30 million.
• Oramed has invested in Alpha Tau Medical Ltd. and RoyaltyVest Ltd. to diversify its investments.
• The company is evaluating potential strategic opportunities to enhance value for its stockholders.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's revenue growth and strategic investments, the net loss and delayed joint venture raise concerns.

Positives

• Revenue increased to $2.0 million due to the HTIT License Agreement.
• Cash and cash equivalents increased to $74.516 million as of March 31, 2025.
• The company is actively pursuing strategic real estate investments.
• Oramed is diversifying its investments through investments in Alpha Tau Medical Ltd. and RoyaltyVest Ltd.

Negatives

• The company experienced a net loss of $7.642 million for Q1 2025.
• Research and development expenses increased significantly.
• The closing of the JV Agreement with HTIT is currently on hold due to U.S.-China trade tensions.

Risks

• Ongoing U.S.-China trade tensions may impact the HTIT joint venture.
• Delays in the HTIT joint venture may affect the Phase 3 clinical trial in the U.S.
• The company is exposed to potential market, liquidity, and execution risks related to its Profit Sharing Loan Agreement.
• Changes in trade policy, including new tariffs and retaliatory measures, by the United States could adversely affect the company's and/or HTIT's ability to consummate the joint venture.
• The company is affected by the political, economic and military risks of having operations in Israel.

Future Outlook

Oramed plans to continue its research and development efforts, particularly for its oral insulin program, and is evaluating potential strategic opportunities to enhance value for its stockholders. The company is also monitoring the situation with the HTIT joint venture and exploring alternative partners and pathways to advance the program independently.

Industry Context

Oramed's focus on oral delivery of therapeutic proteins and vaccines positions it within the innovative drug delivery systems market. The company's progress with its oral insulin program and joint venture with HTIT are relevant to the diabetes treatment market, which is characterized by a growing need for convenient and effective therapies. The company's investments in Scilex, Alpha Tau, and RoyaltyVest reflect a broader trend of pharmaceutical companies diversifying their portfolios and exploring new revenue streams.

Comparison to Industry Standards

• Oramed's Q1 2025 results show a net loss of $7.642 million, which contrasts with companies like Teva Pharmaceutical Industries Ltd., which reported a net profit of $78 million in Q1 2024.
• However, Oramed's revenue increased to $2.0 million due to the HTIT License Agreement, while companies like Mylan N.V. reported revenues of $3.2 billion in Q1 2024.
• Oramed's research and development expenses increased by 87% to $2.206 million, while companies like Johnson & Johnson spent $3.5 billion on R&D in Q1 2024.
• Oramed's cash and cash equivalents increased to $74.516 million as of March 31, 2025, while companies like Pfizer Inc. had $24.5 billion in cash and short-term investments as of March 31, 2024.
• Oramed's investment in Alpha Tau Medical Ltd. is similar to other pharmaceutical companies investing in innovative medical device companies, such as Medtronic's acquisition of Mazor Robotics for $1.6 billion.

Related Party Transactions

• The Subsidiary entered into a consulting agreement with KNRY Ltd., an Israeli company owned by the Company's Chief Scientific Officer.
• The Company entered into a consulting agreement with Shnida Ltd., whereby the Company's President and Chief Executive Officer, through Shnida, provides services as President and Chief Executive Officer of the Company.

Stakeholder Impact

• Shareholders may be concerned about the net loss, but encouraged by the revenue growth and strategic investments.
• Employees may be affected by the potential changes in the oral insulin program and the HTIT joint venture.
• Customers may be impacted by the potential delays in the Phase 3 clinical trial for oral insulin.

Next Steps

• Continue to evaluate the feasibility of a modified structure with HTIT.
• Explore alternative partners and pathways to advance the oral insulin program independently.
• Monitor the situation with the HTIT joint venture and U.S.-China trade tensions.
• Continue to pursue strategic real estate investments.
• Continue to evaluate potential strategic opportunities to enhance value for stockholders.

Key Dates

Keywords

Oramed, Pharmaceuticals, HTIT, Joint Venture, Clinical Trial, Oral Insulin, Scilex, Real Estate, Alpha Tau, RoyaltyVest, Financial Results, Q1 2025